Large-Scale Medicaid Study Finds Prenatal Buprenorphine Exposure Does Not Increase Long-Term Neurodevelopmental Risks

A large study of 2.5M births finds no increased risk of ADHD or autism in children exposed to buprenorphine prenatally compared to methadone.

By: AXL Media

Published: Apr 18, 2026, 4:36 AM EDT

Source: Information for this report was sourced from BMJ Group

Closing the Evidence Gap on Long-Term Fetal Safety

While both buprenorphine and methadone have long been recommended for treating opioid use disorder (OUD) during pregnancy, medical professionals have historically lacked definitive data regarding the long-term neurodevelopmental effects on children. Previous studies established that buprenorphine is associated with better immediate neonatal outcomes—such as lower risk of preterm birth and less severe neonatal abstinence syndrome—but concerns persisted about potential behavioral or cognitive impacts later in life. A new large-scale study, published April 15, 2026, in The BMJ, addresses this uncertainty by following a cohort of children for nearly a decade. Lead author Sabine Friedrich and her colleagues conclude that the evidence strongly supports buprenorphine as a safe, viable option for pregnant individuals, offering reassurance to providers and patients alike.

Medicaid Data Reveals Comparative Advantages Over Methadone

The research team analyzed a massive dataset from US Medicaid health insurance, covering over 2.5 million live births between 2000 and 2018. Within this population, they identified 12,635 children prenatally exposed to buprenorphine and 5,390 children exposed to methadone. After adjusting for influential factors such as maternal age, ethnicity, tobacco use, and mental health conditions, the results indicated that buprenorphine exposure was actually linked to a 19% lower risk of any neurodevelopmental disorder by age eight compared to methadone. Specifically, the data showed an 11% lower risk for ADHD, a 16% lower risk for speech or language disorders, and a 26% lower risk for autism spectrum disorder.

Differentiating Between Prevalent and New Treatment Use

A nuanced finding of the study suggests that the timing of medication initiation may influence outcomes. For women who were already using buprenorphine or methadone before their pregnancy began (prevalent use), buprenorphine exposure was associated with a 38% lower risk of neurodevelopmental disorders compared to methadone. However, this same protective association was not statistically observed in cases where treatment was initiated during the pregnancy itself (new use). The authors noted that while this distinction requires further investigation, the overall data across all trimesters provides a robust foundation for the safety...